Lipoprotein (a), an independent cardiovascular risk marker

Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a causal and independent risk factor for cardiovascular diseases (CVD). The Lp(a)-induced increased risk of CVD may be mediated by both its proatherogenic and prothrombotic mechanisms. Several guidelin...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeedi, Ramesh, Frohlich, Jiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471681/
https://www.ncbi.nlm.nih.gov/pubmed/28702242
http://dx.doi.org/10.1186/s40842-016-0024-x
_version_ 1783243994563608576
author Saeedi, Ramesh
Frohlich, Jiri
author_facet Saeedi, Ramesh
Frohlich, Jiri
author_sort Saeedi, Ramesh
collection PubMed
description Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a causal and independent risk factor for cardiovascular diseases (CVD). The Lp(a)-induced increased risk of CVD may be mediated by both its proatherogenic and prothrombotic mechanisms. Several guidelines recommend screening of Lp(a) level; however, there are few treatment options for the management of patients with elevated Lp(a). Several new medications for Lp(a) are under development. PCSK9 inhibitors, apolipoprotein (a)-antisense, and apolipoprotein(B-100)-antisense mipomersen have shown promising results. Lp(a) reduction will continue to be an active area of investigation.
format Online
Article
Text
id pubmed-5471681
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54716812017-07-12 Lipoprotein (a), an independent cardiovascular risk marker Saeedi, Ramesh Frohlich, Jiri Clin Diabetes Endocrinol Review Article Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a causal and independent risk factor for cardiovascular diseases (CVD). The Lp(a)-induced increased risk of CVD may be mediated by both its proatherogenic and prothrombotic mechanisms. Several guidelines recommend screening of Lp(a) level; however, there are few treatment options for the management of patients with elevated Lp(a). Several new medications for Lp(a) are under development. PCSK9 inhibitors, apolipoprotein (a)-antisense, and apolipoprotein(B-100)-antisense mipomersen have shown promising results. Lp(a) reduction will continue to be an active area of investigation. BioMed Central 2016-03-31 /pmc/articles/PMC5471681/ /pubmed/28702242 http://dx.doi.org/10.1186/s40842-016-0024-x Text en © Saeedi and Frohlich. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review Article
Saeedi, Ramesh
Frohlich, Jiri
Lipoprotein (a), an independent cardiovascular risk marker
title Lipoprotein (a), an independent cardiovascular risk marker
title_full Lipoprotein (a), an independent cardiovascular risk marker
title_fullStr Lipoprotein (a), an independent cardiovascular risk marker
title_full_unstemmed Lipoprotein (a), an independent cardiovascular risk marker
title_short Lipoprotein (a), an independent cardiovascular risk marker
title_sort lipoprotein (a), an independent cardiovascular risk marker
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471681/
https://www.ncbi.nlm.nih.gov/pubmed/28702242
http://dx.doi.org/10.1186/s40842-016-0024-x
work_keys_str_mv AT saeediramesh lipoproteinaanindependentcardiovascularriskmarker
AT frohlichjiri lipoproteinaanindependentcardiovascularriskmarker

Ejemplares similares